Merck Is Partnering With America’s Largest HBCU To Launch a Collaborative Biotechnology Learning Center
NORTHAMPTON, MA / ACCESSWIRE / June 20, 2024 / Building the workforce of tomorrow means investing in the students of...
Pharmaceutical
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT...
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product...
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and...
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
Rapid, robust, and clinically significant reduction in depression symptomsTrials of MB22001 show substantial improvements in mood, energy, creativity, wellbeing, depression...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement NeuronsSOLANA BEACH, Calif., June...
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified...
Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment
Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after...
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure...
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path),...
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening...
Nusano to Host Virtual Event “Office Hours: Radiopharmaceuticals” on June 28, 2024
VALENCIA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, today announced...
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal...
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA)...
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town,...
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s...
Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease
Phase 2 study is designed to evaluate the safety, tolerability, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s...